This review synthesizes the current understanding of sepsis-induced myocardial dysfunction (SIMD), moving the field beyond supportive care toward precision therapies. While challenges remain in addressing the diverse nature of the immune response, profiling dynamic biomarkers, and optimizing treatment timing, the research underscores the potential to use these mechanistic insights to transform SIMD management from general supportive care to targeted functional recovery through precision medicine.

Recent research has unveiled several critical pathways driving SIMD:

RNA Methylation: A new layer of gene regulation, m6A RNA methylation (facilitated by the enzyme METTL3), is central. It “rewires” the cell’s transcriptome to coordinate cell death (apoptosis), a type of inflammatory cell death (pyroptosis), and a form of iron-dependent cell death (ferroptosis).

Extracellular Vesicles (EVs): These tiny messengers have dual roles. They can propagate injury by delivering microRNAs (like microRNA-885-5p) that trigger inflammation. Conversely, they can be engineered to deliver therapeutic cargo (like microRNA-223) to suppress inflammation.

Mitochondrial Dysfunction: Impaired mitochondrial function generates massive reactive oxygen species (ROS), activating the NLRP3 inflammasome (a key inflammatory complex). This metabolic crisis is compounded by the instability of SERCA2a, a protein vital for calcium handling and heart muscle contraction.

The mechanistic discoveries are paving the way for targeted treatments:

Neuro-Modulation: Strategies that rebalance the neuroimmune interaction, such as electroacupuncture and noninvasive vagus nerve stimulation, show promise in reducing cardiac injury.

Targeting the Immune System: Preclinical success has been seen with interventions that block the Complement hyperactivation (specifically the C5a-C5a receptor axis) and the use of immune checkpoint inhibitors (like anti-PD-L1 antibodies).

Read More